CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Monoclonal antibodies like etesevimab have lost efficacy against Omicron subvariants, necessitating innovative solutions.

Scientists reveal that reactivation of Epstein-Barr virus (EBV), driven by TGFβ-induced immune suppression, is a key driver ...

Clinical-stage biotechnology company Vaxxas has announced the publication of data supporting the potential use of its ...

VUMC received up to $30M to develop AI for antibody therapy discovery, aiming to create an antibody-antigen atlas and ...

New data announced by Vaxxas supports the use of its high-density microarray patch (HD-MAP) technology to deliver DNA-based vaccines.

Ensitrelvir PEP was safe and effective for COVID-19 prevention among household contacts when administered after the onset of symptoms in an index patient.

New COVID Variant: In 2019, the world saw the emergence of the deadliest virus outbreak SARS-CoV-2, which caused COVID-19. This deadly virus evaded the human immune system, targeting the ...

Scientists found that it can bind to human ACE2 receptors, similar to SARS-CoV-2 (the virus behind COVID-19). This suggests it has the potential for animal-to-human transmission. Experts note that ...

The discovery raises concerns about the virus's similarity to SARS-CoV-2 and its potential implications.

Scientists found that the new virus can bind to human ACE2, making it similar to SARS-CoV-2 and NL63 (a common cold virus). The new virus called HKU5-CoV-2, discovered in bats in China ...